PE20120402A1 - Piperidinas sustituidas como antagonistas par-1 - Google Patents

Piperidinas sustituidas como antagonistas par-1

Info

Publication number
PE20120402A1
PE20120402A1 PE2011002009A PE2011002009A PE20120402A1 PE 20120402 A1 PE20120402 A1 PE 20120402A1 PE 2011002009 A PE2011002009 A PE 2011002009A PE 2011002009 A PE2011002009 A PE 2011002009A PE 20120402 A1 PE20120402 A1 PE 20120402A1
Authority
PE
Peru
Prior art keywords
oxidotiomorfolin
methanone
oxadiazol
piperidin
par
Prior art date
Application number
PE2011002009A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Rohrig
Grande Yolanda Cancho
Eckhard Bender
Katja Zimmermann
Anja Buchmuller
Christoph Gerdes
Mark Jean Gnoth
Kersten Matthias Gericke
Mario Jeske
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20120402A1 publication Critical patent/PE20120402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIPERIDINA DE FORMULA (I), DONDE R1 ES TRIFLUOROMETILO, 1,1-DIFLUOROETILO, 2,2,2-TRIFLUOROETILO, ENTRE OTROS; R2 ES 2-HIDROXIET-1-ILO, 2-METOXIET-1-ILO, CICLOPROPILO, ENTRE OTROS; R3 ES OXIDOTIOMORFOLINILO O DIOXIDOTIOMORFOLINILO. SON COMPUESTOS PREFERIDOS: {3-[3-(2-METOXIETIL)-1,2,4-OXADIAZOL-5-IL]-5-[4-(TRIFLUOROMETOXI)FENIL]PIPERIDIN-1-IL}-(OXIDOTIOMORFOLIN-4-IL)METANONA, {3-(3-CICLOPROPIL-1,2,4-OXADIAZOL-5-IL)-5-[4-(TRIFLUOROMETOXI)FENIL]PIPERIDIN-1-IL}-(1-OXIDOTIOMORFOLIN-4-IL)METANONA, {3-[3-(2-ETOXIETIL)-1,2,4-OXADIAZOL-5-IL]-5-(4-ETILFENIL)PIPERIDIN-1-IL}-(1-OXIDOTIOMORFOLIN-4-IL)METANONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES ACTIVADOS POR PROTEASA (PAR-1) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES, TROMBOEMBOLICOS, TUMORALES, ENTRE OTROS
PE2011002009A 2009-05-27 2010-05-18 Piperidinas sustituidas como antagonistas par-1 PE20120402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009022894A DE102009022894A1 (de) 2009-05-27 2009-05-27 Substituierte Piperidine

Publications (1)

Publication Number Publication Date
PE20120402A1 true PE20120402A1 (es) 2012-04-18

Family

ID=42537882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002009A PE20120402A1 (es) 2009-05-27 2010-05-18 Piperidinas sustituidas como antagonistas par-1

Country Status (29)

Country Link
US (3) US8440657B2 (es)
EP (1) EP2435431A1 (es)
JP (1) JP5728687B2 (es)
KR (1) KR20120024652A (es)
CN (1) CN102482270B (es)
AR (1) AR076709A1 (es)
AU (1) AU2010252339B2 (es)
BR (1) BRPI1012775A2 (es)
CA (1) CA2763386A1 (es)
CO (1) CO6470822A2 (es)
CR (1) CR20110627A (es)
CU (1) CU24011B1 (es)
DE (1) DE102009022894A1 (es)
EA (1) EA021944B1 (es)
HK (1) HK1171450A1 (es)
HN (1) HN2011003102A (es)
IL (1) IL215903A0 (es)
MA (1) MA33291B1 (es)
MX (1) MX2011012507A (es)
MY (1) MY166555A (es)
NZ (1) NZ596621A (es)
PE (1) PE20120402A1 (es)
SG (1) SG175759A1 (es)
TN (1) TN2011000596A1 (es)
TW (1) TWI464166B (es)
UA (1) UA107576C2 (es)
UY (1) UY32652A (es)
WO (1) WO2010136138A1 (es)
ZA (1) ZA201108609B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
CN103842356B (zh) 2011-10-07 2017-03-15 武田药品工业株式会社 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物
JP5900182B2 (ja) * 2012-06-21 2016-04-06 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の製造方法
JP6197348B2 (ja) * 2013-04-25 2017-09-20 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の保存安定性の向上方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
CA2462374C (en) 2001-10-15 2011-01-18 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
EA200700118A1 (ru) 2004-06-24 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве лекарственных средств
US20060009491A1 (en) 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1758580A4 (en) 2004-06-24 2008-01-16 Incyte Corp N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
US20060122197A1 (en) 2004-08-10 2006-06-08 Wenqing Yao Amido compounds and their use as pharmaceuticals
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
EP1705960A1 (en) 2005-03-21 2006-09-27 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Electroluminescent lamp
US20070066584A1 (en) 2005-09-21 2007-03-22 Wenqing Yao Amido compounds and their use as pharmaceuticals
BRPI0707408A2 (pt) 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
WO2007101270A1 (en) 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070293529A1 (en) 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
KR20100114018A (ko) 2007-11-30 2010-10-22 바이엘 쉐링 파마 악티엔게젤샤프트 헤테로아릴-치환된 피페리딘
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022892A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine

Also Published As

Publication number Publication date
HK1171450A1 (en) 2013-03-28
BRPI1012775A2 (pt) 2019-09-24
US20100305111A1 (en) 2010-12-02
EP2435431A1 (de) 2012-04-04
WO2010136138A1 (de) 2010-12-02
ZA201108609B (en) 2013-02-27
EA021944B1 (ru) 2015-10-30
DE102009022894A1 (de) 2010-12-02
CA2763386A1 (en) 2010-12-02
IL215903A0 (en) 2012-01-31
CU24011B1 (es) 2014-06-27
CU20110214A7 (es) 2012-03-15
AU2010252339A1 (en) 2011-12-08
CN102482270A (zh) 2012-05-30
TWI464166B (zh) 2014-12-11
AR076709A1 (es) 2011-06-29
JP5728687B2 (ja) 2015-06-03
KR20120024652A (ko) 2012-03-14
MY166555A (en) 2018-07-16
CR20110627A (es) 2012-03-22
JP2012528089A (ja) 2012-11-12
UA107576C2 (ru) 2015-01-26
TN2011000596A1 (en) 2013-05-24
AU2010252339B2 (en) 2014-10-23
NZ596621A (en) 2013-12-20
CO6470822A2 (es) 2012-06-29
US8202862B2 (en) 2012-06-19
HN2011003102A (es) 2015-02-23
TW201107319A (en) 2011-03-01
CN102482270B (zh) 2015-02-25
US20120135985A1 (en) 2012-05-31
US20130252948A1 (en) 2013-09-26
EA201190313A1 (ru) 2012-05-30
MA33291B1 (fr) 2012-05-02
US8440657B2 (en) 2013-05-14
MX2011012507A (es) 2011-12-14
SG175759A1 (en) 2011-12-29
UY32652A (es) 2010-12-31

Similar Documents

Publication Publication Date Title
PE20120402A1 (es) Piperidinas sustituidas como antagonistas par-1
SV2010003642A (es) Compuestos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20141059A1 (es) Indazoles
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20141033A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
PE20160859A1 (es) Inhibidores de la quinasa reguladora de la senal de apoptosis
PE20150220A1 (es) Compuestos de tetrahidropirazolopirimidina
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141686A1 (es) Compuestos de piperazina alquilados como inhibidores de actividad btk
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA200870521A1 (ru) Замещенные спироциклические антагонисты cgrp-рецепторов
PE20110136A1 (es) Compuestos organicos
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
AR067090A1 (es) Espiriciclos como inhibidores de la 11- beta hidroxiesteroide deshidrogenasa de tipo 1
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20091026A1 (es) Piperidinas heteroaril-sustituidas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed